What is Corvus Pharmaceuticals's gain/loss on asset sales?

Corvus Pharmaceuticals (CRVS) reported gain/loss on asset sales of $1.25K in Q4 2024.

What does gain/loss on asset sales mean?

Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.

Corvus Pharmaceuticals CRVS Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Iovance Biotherapeutics, Inc.IOVA

-$28K+36.4%

Vor BiopharmaVOR

$0+100%

Candel Therapeutics, Inc.CADL

-$300K—

ImmunomeIMNM

-$79K—

Other financials

Income statement

See full

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Balance sheet

See full

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Cash flow

See full

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Valuation

See full

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Returns & leverage

See full

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Corvus Pharmaceuticals’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corvus Pharmaceuticals's gain/loss on asset sales?: Corvus Pharmaceuticals (CRVS) reported gain/loss on asset sales of $1.25K in Q4 2024.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.